Micheliolide provides protection of mice against Staphylococcus aureus and MRSA infection by down-regulating inflammatory response.

ABSTRACT: A major obstacle to therapy in intensive care units is sepsis caused by severe infection. In recent years gram-positive (G⁺) bacteria, most commonly staphylococci, are thought to be the main pathogens. Micheliolide (MCL) was demonstrated to provide a therapeutic role in rheumatoid arthritis, inflammatory intestinal disease, colitis-associated cancer, and lipopolysaccharide (LPS, the main component of G^- bacterial cell wall) induced septic shock. We proved here that MCL played an anti-inflammatory role in Staphylococcus aureus (S. aureus) and methicillin-resistant S. aureus (MRSA) induced peritonitis. It inhibited the expression of inflammatory cytokines and chemokines in macrophages and dendritic cells upon stimulation with peptidoglycan (PGN, the main cell wall compo

SUBMITTER: Jiang X 

PROVIDER: S-EPMC5292736 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature